Dr Sumanta Kumar Pal (City of Hope, California, USA), Prof Thomas Powles (Barts Cancer Centre, London, UK), Prof Viktor Grünwald (University Hospital Essen, Essen, Germany) and Dr Stephanie Berg (Dana-Farber Cancer Institute, Boston, USA) discuss the latest updates in mRCC.

The panel talks about the multi-institution analysis of outcomes with first-line systemic therapy for 99 patients with metastatic chromophobe renal cell carcinoma.

They also discuss the phase 3 CLEAR, KEYNOTE-426 and CheckMate 67T trials.

Belzutifan in patients with advanced clear cell renal cell carcinoma was also discussed.